Gemin X Announces Data Presentation for its Novel, Targeted Cancer Therapy Obatoclax at the 26th Chemotherapy Foundation Symposium
MALVERN, Pa. & MONTREAL–(BUSINESS WIRE)–Oct 31, 2008 – Gemin X Pharmaceuticals announced today that clinical data from a Phase 1/2 study of obatoclax (GX15-070), the Company’s innovative pan Bcl-2 inhibitor, will be presented during The 26th… Read more…